Education
About Us
Working with TipRanks
Follow Us
Britannia Life Sciences Inc (TSE:BLAB)
:BLAB
BLAB Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.14
Previous CloseN/A
Volume35.00K
Average Volume (3M)73.07K
Market Cap
C$15.41M
Enterprise ValueC$13.78M
Total Cash (Recent Filing)C$15.89M
Total Debt (Recent Filing)C$183.11K
Price to Earnings (P/E)0.3
Beta-1.56
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageMaterial reduction in debt versus equity meaningfully lowers refinancing and interest-rate risk for the medium term. A repaired balance sheet increases financial flexibility to fund R&D or operations without immediate dilution, improving survivability across 2–6 month to multi-quarter horizons.
Past Operating Cash GenerationA prior track record of positive operating cash flow demonstrates the business can generate cash under certain operating conditions. This indicates operational levers exist to restore cash generation, reducing long-term structural risk compared with firms that have never generated operating cash.
Positive ROEA positive trailing ROE, even if modest, shows the company is able to convert equity into reported profit in the latest period. Sustained positive ROE supports long-term capital efficiency and provides a foundation for eventual reinvestment or external financing on more favourable terms.
Bears Say
Negative Cash FlowMeaningful negative operating and free cash flow implies ongoing cash burn and a reliance on financing to continue operations. Over a multi-quarter horizon this raises dilution and liquidity risk, constraining R&D spend and strategic options unless cash generation is restored or financing secured.
Volatile, Low-quality RevenueNegative trailing revenue and outsized growth metrics signal volatile or one-off revenue recognition. Reliance on non-operating items for profitability undermines sustainable earnings power, making future margin and cash forecasts highly uncertain and increasing execution risk over months.
Historical Balance-sheet StressA history of high leverage and past negative equity indicates structural vulnerability in downturns and a precedent of tight liquidity. Even with recent repair, legacy credit and governance implications can limit access to capital and worsen terms if operational setbacks reoccur.
Britannia Life Sciences Inc News
BLAB FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was C$0.05 and its highest was C$0.14 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is C$15.41M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Aug 04, 2026 which is in 144 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Mar 02, 2026. The company reported C$0.075 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.075.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of C$0.075 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in TSE:BLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.
Technical Analysis
Hemostemix
―
Innovotech
―
Sirona Biochem
―
Glow LifeTech
―
Telescope Innovations Corp
―